{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:41:21Z","timestamp":1790077281057,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1038\/sj.bjc.6602752","type":"journal-article","created":{"date-parts":[[2005,10,13]],"date-time":"2005-10-13T07:36:46Z","timestamp":1129189006000},"page":"647-651","source":"Crossref","is-referenced-by-count":46,"title":["Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer"],"prefix":"10.1038","volume":"93","author":[{"given":"J","family":"Hasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Ton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Mullamitha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Clamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"McNeilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G C","family":"Jayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,9,13]]},"reference":[{"key":"BF6602752_CR1","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1200\/JCO.1993.11.10.1957","volume":"11","author":"JD Ahlgren","year":"1993","unstructured":"Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, Ueno W, Wampler GL, Yeung KY, Alt D, Fryer JG (1993) Hormonal palliation of chemo resistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 11: 1957\u20131968","journal-title":"J Clin Oncol"},{"key":"BF6602752_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1006\/gyno.1996.4520","volume":"64","author":"JF Boggess","year":"1997","unstructured":"Boggess JF, Soules MR, Goff BA, Greer BE, Cain JM, Tamimi HK (1997) Serum inhibin and disease status in women with ovarian granulosa cell tumors. Gynecol Oncol 64: 64\u201369","journal-title":"Gynecol Oncol"},{"key":"BF6602752_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1006\/gyno.1994.1170","volume":"4","author":"PJ Connor","year":"1994","unstructured":"Connor PJ, Buller RE, Conn PM (1994) Effects of GnRH analogs on six ovarian cancer cell lines in culture. Gynecol Oncol 4: 80\u201386","journal-title":"Gynecol Oncol"},{"key":"BF6602752_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1136\/bmj.302.6771.259","volume":"302","author":"RA Eeles","year":"1991","unstructured":"Eeles RA, Tan S, Wiltshaw E, Fryatt I, A\u2019Hern RP, Shepherd JH, Harmer CL, Blake PR, Chilvers CE (1991) Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 302: 259\u2013262","journal-title":"BMJ"},{"key":"BF6602752_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0960-0760(97)00189-1","volume":"65","author":"G Emons","year":"1998","unstructured":"Emons G, Muller V, Ortmann O, Schulz KD (1998) Effects of LHRH-analogues on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol 65: 199\u2013206","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BF6602752_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0277-5379(89)90011-4","volume":"25","author":"G Emons","year":"1989","unstructured":"Emons G, Pahwa G, Brack C, Sturm R, Oberhauser F, Knuppen R (1989) Gonadotropin-releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Clin Oncol 25: 215\u2013221","journal-title":"Eur J Clin Oncol"},{"key":"BF6602752_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/oxfordjournals.humrep.a138714","volume":"9","author":"G Emons","year":"1994","unstructured":"Emons G, Schally AV (1994) The use of luteinising hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod 9: 176\u2013194","journal-title":"Hum Reprod"},{"key":"BF6602752_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-642-59587-5_7","volume":"153","author":"G Emons","year":"2000","unstructured":"Emons G, Schulz KD (2000) Primary and salvage therapy with LH-RH analogues in ovarian cancer. Recent Results Cancer Res 153: 83\u201394, 202.","journal-title":"Recent Results Cancer Res"},{"key":"BF6602752_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","volume":"51","author":"RT Greenlee","year":"2001","unstructured":"Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics, 2001. CA Cancer J Clin 51: 15\u201336","journal-title":"CA Cancer J Clin"},{"key":"BF6602752_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1365-2265.1994.tb02504.x","volume":"40","author":"NP Groome","year":"1994","unstructured":"Groome NP, Illingworth PJ, O\u2019Brien M, Cooke I, Ganesan TS, Baird DT, McNeilly AS (1994) Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin Endocrinol 40: 717\u2013723","journal-title":"Clin Endocrinol"},{"key":"BF6602752_CR11","first-page":"1401","volume":"81","author":"NP Groome","year":"1996","unstructured":"Groome NP, Illingworth PJ, O\u2019Brien M, Pai R, Rodger FE, Mather J, McNeilly AS (1996) Measurement of dimeric inhibin-B throughout the human menstrual cycle. J Clin Endocrinol Metab 81: 1401\u20131405","journal-title":"J Clin Endocrinol Metab"},{"key":"BF6602752_CR12","first-page":"2926","volume":"80","author":"NP Groome","year":"1995","unstructured":"Groome NP, Illingworth PJ, O\u2019Brien M, Priddle J, Weaver K, McNeilly AS (1995) Quantification of inhibin Pro-alpha C-containing forms in human serum by a new ultra sensitive two-site enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 80: 2926\u20132932","journal-title":"J Clin Endocrinol Metab"},{"key":"BF6602752_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1006\/gyno.2000.5863","volume":"78","author":"C Grundker","year":"2000","unstructured":"Grundker C, Volker P, Schulz KD, Emons G (2000) Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynaecological cancers. Gynecol Oncol 78: 194","journal-title":"Gynecol Oncol"},{"key":"BF6602752_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O","volume":"68","author":"KD Hatch","year":"1991","unstructured":"Hatch KD, Beecham JB, Blessing JA, Creasman WT (1991) Responsiveness of patients with advanced ovarian cancer to tamoxifen: a Gynaecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68: 269\u2013271","journal-title":"Cancer"},{"key":"BF6602752_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJM199311183292104","volume":"329","author":"DL Healy","year":"1993","unstructured":"Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M, Grant P, Day AJ, Rome R, Campbell JJ (1993) Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 329: 1539\u20131542","journal-title":"N Engl J Med"},{"key":"BF6602752_CR16","first-page":"3627","volume":"19","author":"LS Hofstra","year":"1999","unstructured":"Hofstra LS, Mourits MJ, de Vries EG, Mulder NH, Willemse PH (1999) Combined treatment with goserelin and tamoxifen in patients with advanced chemotherapy resistant ovarian cancer. Anticancer Res 19: 3627\u20133630","journal-title":"Anticancer Res"},{"key":"BF6602752_CR17","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/0277-5379(88)90046-6","volume":"24","author":"A Howell","year":"1988","unstructured":"Howell A, Mackintosh J, Jones M, Radford J, Wagstaff J, Sellwood RA (1988) The definition of the \u2018no change\u2019 category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 24: 1567\u20131572","journal-title":"Eur J Cancer Clin Oncol"},{"key":"BF6602752_CR18","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1002\/1097-0142(19941101)74:9<2555::AID-CNCR2820740925>3.0.CO;2-X","volume":"74","author":"A Imai","year":"1994","unstructured":"Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T (1994) Gonadotropin-releasing hormone receptor in gynaecologic tumours. Cancer 74: 2555\u20132561","journal-title":"Cancer"},{"key":"BF6602752_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1006\/gyno.1994.1291","volume":"55","author":"T Jobling","year":"1994","unstructured":"Jobling T, Mamers P, Healy DL, MacLachlan V, Burger HG, Quinn M, Rome R, Day AJ (1994) A prospective study of inhibin in granulosa cell tumors of the ovary. Gynecol Oncol 55: 285\u2013289","journal-title":"Gynecol Oncol"},{"key":"BF6602752_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3109\/09513599209024990","volume":"6","author":"A Kauppila","year":"1992","unstructured":"Kauppila A, Bangah M, Burger H, Martikainen H (1992) GnRH agonist analog therapy in advanced\/recurrent granulosa cell tumors: further evidence of a role of inhibin in monitoring response to treatment. Gynecol Endocrinol 6: 271\u2013274","journal-title":"Gynecol Endocrinol"},{"key":"BF6602752_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.1989.7.1.115","volume":"7","author":"JJ Kavanagh","year":"1989","unstructured":"Kavanagh JJ, Roberts W, Townsend P, Hewitt S (1989) Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol 7: 115\u2013118","journal-title":"J Clin Oncol"},{"key":"BF6602752_CR22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/0959-8049(94)90545-2","volume":"30A","author":"SP Langdon","year":"1994","unstructured":"Langdon SP, Crew AJ, Ritchie AA, Muir M, Wakeling A, Smyth JF, Miller WR (1994) Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. Eur J Cancer 30A: 682\u2013686","journal-title":"Eur J Cancer"},{"key":"BF6602752_CR23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/bjc.1992.126","volume":"65","author":"MJ Lind","year":"1992","unstructured":"Lind MJ, Cantwell BM, Millward MJ, Robinson A, Proctor M, Simn D, Carmichael J, Harris AL (1992) A phase II trial of goserelin (zoladex) in relapsed epithelial ovarian cancer. Br J Cancer 65: 621\u2013623","journal-title":"Br J Cancer"},{"key":"BF6602752_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","volume":"5","author":"M Markman","year":"2000","unstructured":"Markman M, Bookman MA (2000) Second-line treatment of ovarian cancer. Oncologist 5: 26\u201335","journal-title":"Oncologist"},{"key":"BF6602752_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1\u20136","journal-title":"N Engl J Med"},{"key":"BF6602752_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1006\/gyno.2002.6778","volume":"86","author":"L Paskeviciute","year":"2002","unstructured":"Paskeviciute L, Roed H, Engelholm SA (2002) No rules without exception: long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer. Gynecol Oncol 86: 297\u2013301","journal-title":"Gynecol Oncol"},{"key":"BF6602752_CR27","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1210\/jcem.85.11.6997","volume":"85","author":"A Perheentupa","year":"2000","unstructured":"Perheentupa A, Critchley HO, Illingworth PJ, McNeilly AS (2000) Enhanced sensitivity to steroid-negative feedback during breast-feeding: low-dose estradiol (transdermal estradiol supplementation) suppresses gonadotropins and ovarian activity assessed by inhibin B. J Clin Endocrinol Metab 85: 4280\u20134286","journal-title":"J Clin Endocrinol Metab"},{"key":"BF6602752_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1006\/gyno.2001.6489","volume":"84","author":"JL Perez-Garcia","year":"2002","unstructured":"Perez-Garcia JL, Carrasco EM (2002) Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol 84: 201\u2013209","journal-title":"Gynecol Oncol"},{"key":"BF6602752_CR29","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","volume":"92","author":"MJ Piccart","year":"2000","unstructured":"Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S (2000) Randomized intergroup trial of cisplatin\u2013paclitaxel versus cisplatin\u2013cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699\u2013708","journal-title":"J Natl Cancer Inst"},{"key":"BF6602752_CR30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/clinchem\/45.5.651","volume":"45","author":"DM Robertson","year":"1999","unstructured":"Robertson DM, Cahir N, Burger HG, Mamers P, McCloud PI, Pettersson K, McGuckin M (1999) Combined inhibin and CA125 assays in the detection of ovarian cancer. Clin Chem 45: 651\u2013658","journal-title":"Clin Chem"},{"key":"BF6602752_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0303-7207(02)00060-6","volume":"191","author":"DM Robertson","year":"2002","unstructured":"Robertson DM, Stephenson T, Pruysers E, Burger HG, McCloud P, Tsigos A, Groome N, Mamers P, McNeilage J, Jobling T, Healy D (2002) Inhibins\/activins as diagnostic markers for ovarian cancer. Mol Cell Endocrinol 191: 97\u2013103","journal-title":"Mol Cell Endocrinol"},{"key":"BF6602752_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1046\/j.1525-1438.1992.02030160.x","volume":"2","author":"P Sevelda","year":"1992","unstructured":"Sevelda P, Vavra N, Fitz R, Barrada M, Salzer H, Baur M, Dittrich C (1992) Goserelin a GnRH analogue as third-line therapy of refractory epithelial ovarian cancer. Int J Gynecol Cancer 2: 160\u2013162","journal-title":"Int J Gynecol Cancer"},{"key":"BF6602752_CR33","first-page":"417","volume":"8","author":"BJ Slotman","year":"1988","unstructured":"Slotman BJ, Rao BR (1988) Ovarian cancer (review): aetiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Res 8: 417\u2013434","journal-title":"Anticancer Res"},{"key":"BF6602752_CR34","unstructured":"Williams CJ (2001) Tamoxifen for relapsed ovarian cancer. Cochrane database System Rev, (1): CD001034"},{"key":"BF6602752_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.8755-8920.2000.440206.x","volume":"44","author":"W Zheng","year":"2000","unstructured":"Zheng W, Lu JJ, Luo F, Hsieh J, Wang CY, Zhang C, Chang L, Cho MM, Stanczyk FZ (2000) Tumor stroma as the main source of inhibin production in ovarian epithelial tumors. Am J Reprod Immunol 44: 104\u2013113","journal-title":"Am J Reprod Immunol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602752.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602752","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602752.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:17:51Z","timestamp":1684412271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["BF6602752"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602752","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}